CharlesRiver

Charles River
Lex專欄:無錫藥明康德的價值


美國製藥商業Charles River對無錫藥明康德的收購,承認了中國在醫藥領域的競爭優勢。在許多附加值更高的領域,這種優勢正變得日益明顯。

The rule of thumb in the pharmaceuticals industry is that it takes a decade to go “from molecule to market”. In fact, it often takes as long as 16 years and plenty of money is spent over that time, including on the 10,000 or so compounds that fail for each drug that becomes a success. In a rare acquisition of a Chinese company involved in research and development, Charles River Laboratories is buying Wuxi Pharma Tech for $1.6bn in cash and stock to capture a bigger slice of that expenditure.

製藥業的經驗之談是:從「分子到市場」要花費10年的時間。事實上,這段過程往往要花費16年,而且其間要投入大量金錢,包括在每種藥物獲得成功之前失敗的那1萬多種化合物上的投入。在一筆頗爲罕見的針對中國藥品研發企業的交易中,Charles River Laboratories以16億美元的現金加股票形式收購了無錫藥明康德(WuXi AppTec),希望能夠藉此節省一大筆這類支出。

您已閱讀25%(684字),剩餘75%(2045字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×